Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy.
PMID: 26386408
2015
Transactions of the Royal Society of Tropical Medicine and Hygiene
Abstract: Of the 23 patients in whom HBV-DNA sequencing was successful, 17 had lamivudine-resistant HBV strains harbouring rtM204V/I mutations accompanied by secondary/compensatory mutations.
Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment.
PMID: 26382925
2015
The Journal of general virology
Abstract: Consistent with previous studies, mutation rtM204I was found to be highly resistant to LDT.
Abstract: Furthermore, double mutations rtL80I/M204I and rtL80V/M204V had replication efficiency similar to that of rtL80I and rtL80V, respectively.
Abstract: In vitro replication efficiency analyses showed that the RT mutations had different impacts on HBV replication, with a tendency of rtM204I>rt
A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation.
PMID: 26349829
2015
Antimicrobial agents and chemotherapy
Abstract: Both the 3TC/ETV dually resistant L180M/M204I mutant and the adefovir (ADV)-resistant A181T/N236T mutant were as susceptible to 3711 as wild-type HBV.
Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.
Discussion: Approximately 2-, 3-, 4-, and 7-fold higher replication capacity was observed when the rtL269I mutation was introduced to WT, rtM204I, rtV173L+M204I, and rtM129L+V173L+M204I+H337N mutants, respectively (Fig 2D).
Discussion: Here, it must be noted that the antiviral resistance and reduced polymerase activity conferred by the rtM204I mutant HBV polymerase could be explained by a deformed catalytic site; the bulky side chai
Detection and analysis of resistance mutations of hepatitis B virus.
PMID: 26309637
2015
International journal of clinical and experimental medicine
Abstract: L180M, M204I and M204V were associated with the resistance to lamivudine and telbivudine; L180M, M204I, M204V and V173L were associated with the resistance to entecavir; A181T, N236T and N/H238T were related to the resistance to adefovir.
Abstract: Of single base mutation, L180M, M204I, M204V and V173L had higher prevalence, and the incidence of L180M was closely related to the genotype of HBV.
YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy.
Discussion: The results of mutations were similar to those of the previous studies reporting that the most common mutation affects the highly conserved YMDD motif, resulting in a methionine to valine or isoleucine substitution at codon 204 (M204V/I) and between them, M204I mutant is significantly more resistant to LAM than the M204V mutant.
Discussion: The study found M204I as the dominant mutation in all LAM resistant patients.
Discussion: These findings, consistent with previous studies, demonstrated that the most common mutation affects the highly conserved motif in the catalytic domain of the HBV P gene is M204I.
Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro.
PMID: 26220282
2015
BMC complementary and alternative medicine
Abstract: METHODS: HBV harboring LMV-resistant mutations (rtM204I, rtM204V, and rtM204S) in the P gene at the YMDD ((203)tyrosine-methionine-aspartate-aspartate(206)) reverse transcriptase (RT) active site were generated and their sensitivity to Phyllanthus urinaria koreanis extract examined.
Introduction: M204V/I mutations associated with LMV and LdT resistance als
Result: M204V or M204I are the most frequently observed mutations in this region, and confer resistance to LMV, LdT, and ETV.
Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone.
Abstract: Seven patients had evidence of virological rebound, of whom 6 had evidence of rtM204V/I mutation and 1 had recurrence of hepatocellular carcinoma with low-level rebound and wild-type virus.
Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.
PMID: 26005376
2015
International journal of medical sciences
Abstract: Moreover, no LAM-resistant rtM204I/V or ETV-resistant variants were detected during the 27-36 months of combination therapy.
Result: During 27-36 months of combination treatment, no LAM-resistant variants (rtM204I/V with or without rtL180M) or ETV-resistant variants (rtT184, rtS202, or rtM250) were detected in the viral population.
Discussion: In addition, no LAM-resistant rtM204I/V or ETV-resistant variants were selected during 27-36 months of combination therapy.
Discussion: It should be noted that during ADV-ETV combination rescue therapy, although the replic
[The drug resistance mutation detection and relevant factors analysis of HBV P region in chronic hepatitis B patients in Weifang City, Shandong Province].
HBV mutation literature information.
PMID: 
2015
Transactions of the Royal Society of Tropical Medicine and Hygiene
Browser Board
Co-occurred Entities
Filtrator
ViMRT